The Efficacy of Cancer Immunotherapies Is Compromised by Helicobacter pylori Infection
An erratum on
The efficacy of cancer immunotherapies is compromised by Helicobacter pylori infection
by Oster P, Vaillant L, McMillan B and Velin D (2022) 13:899161. doi: 10.3389/fimmu.2022.899161
An omission to the funding section of the original article was made in error. The following sentence has been added: “Open access funding provided by University of Lausanne”.
The original version of this article has been updated.
Keywords: Helicobacter pylori, cancer, immunotherapy, personalized medicine, gut microbiota, immune checkpoint inhibitors
Citation: Frontiers Production Office (2023) Erratum: The efficacy of cancer immunotherapies is compromised by Helicobacter pylori infection. Front. Immunol. 14:1183107. doi: 10.3389/fimmu.2023.1183107
Received: 09 March 2023; Accepted: 09 March 2023;
Published: 21 March 2023.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2023 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Production Office, production.office@frontiersin.org